Placeholder

Emerging Market: China

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Whether it is partnering, acquisitions, or the expansion of operations, China spells opportunity for the pharmaceutical industry.
Increasingly, global pharmaceutical companies are either expanding their own operations within China or choosing to partner with China-based companies.
According to IMS Health, China is expected to become the world’s third-largest prescription drug market in 2011 and the second largest by 2020. The industry is growing significantly, with statistics from the Ministry of Industry and Information Technology showing value-added output of China’s pharmaceutical…

Sidebars:
China: Healthcare System Fast Facts (2005 – 2009)
The Health Landscape
Investing in China

Experts
Jonathan Adams. Director of Research Evaluation, Thomson Reuters, a leading source of intelligent information for businesses and professionals. For more information, visit thomsonreuters.com.
Friedhelm Blobel, Ph.D.
CEO and President, SciClone Pharmaceuticals, a China-centric specialty pharmaceutical ­company with a product portfolio of novel therapies for cancer and infectious ­diseases. For more information, visit ­sciclone.com.
Zhong Chongyu. General Manager, Ethypharm, China, an innovative drug delivery ­organization. For more ­information, visit ethypharm.com.
Mandy Chui. Practice Leader, Pricing and Market Access, IMS Health Consulting, Asia Pacific, a provider of market intelligence to the ­pharmaceutical and healthcare ­industries. For more information, visit imshealth.com.
Nick Colucci. President and CEO, Publicis Healthcare ­Communications Group, a member of Publicis Groupe, which is one of the largest healthcare ­communications groups in the world. For more information, visit publicishealthcare.com.
Joe Jimenez. CEO, Novartis, a global healthcare ­company whose diverse ­portfolio spans ­innovative ­pharmaceuticals, generics, ­vaccines and ­diagnostics, and consumer health products. For more information, visit novartis.com.
Jeanie Kwon. Senior Director, Regulatory Operations, Image Solutions (ISI), a provider of submissions solutions, process services, and consulting to life-sciences companies. For more information, visit imagesolutions.com.
Adele Li. Head of Marketing Insights, Shanghai, ­Kantar Health, a global consultancy and marketing insights organization, and a strategic decision support partner to the life-sciences industry. For more ­information, visit kantarhealth.com.
Albert Liou. Corporate VP and General Manager, Asia/Pacific, Parexel ­International, a global bio/pharmaceutical services organization that operates in 70 locations throughout 54 countries around the world, including China. For more information, visit parexel.com.

FEEDBACK